线粒体移植作为一种新的治疗方法,用于奇异性炎症性肌肉病的治疗
Jeong Yeon Kim1, Young Cheol Kang2, Min Jung Kim3
1Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Annals of the rheumatic diseases
|February 1, 2025
概括
线粒体移植 (PN-101) 显示出治疗异常性炎症性肌肉病 (IIM) 的前景. 这种疗法在临床前模型和早期人体试验中改善了肌肉功能并减少了炎症,表明作为一种新的IIM治疗的潜力.
科学领域:
- 线粒体医学是指线粒体医学.
- 再生医学是一种再生医学.
- 免疫学 免疫学 免疫学
背景情况:
- 异常性炎症性肌肉病变 (IIM) 的特征是肌肉炎症和功能障碍,通常与线粒体缺陷有关.
- 目前对耐火性IIM的治疗有局限性,需要新的治疗策略.
研究的目的:
- 评估从人类带介质干细胞中获得的线粒体移植 (PN-101) 的疗效和安全性,用于治疗IIM.
- 评估PN-101在体外和体内IIM模型和第一次在人体上的临床试验.
主要方法:
- PN-101的有效性在患者衍生的IIM肌细胞和肌炎 (CIM) 的小鼠模型中进行了测试.
- 一个1/2a期临床试验评估了PN-101在9名耐火IIM成年患者的安全性和有效性.
主要成果:
- PN-101增强了IIM肌细胞中的线粒体功能和肌体发生,并改善了细胞活力.
- 在体内,PN-101降低了肌肉炎的严重程度,产生了抗炎作用,并恢复了代谢平衡.
- 临床试验没有显示严重的不良事件,并且在IIM患者的结果中显示出最小的改善.
结论:
- 使用PN-101进行线粒体移植是IIM的潜在新疗法.
- PN-101可能通过修复线粒体损伤和减少肌肉炎症来起作用.
更多相关视频
10:03Transplantation of Induced Pluripotent Stem Cell-derived Mesoangioblast-like Myogenic Progenitors in Mouse Models of Muscle Regeneration
Published on: January 20, 2014
9.5K
11:13MitoCeption: Transferring Isolated Human MSC Mitochondria to Glioblastoma Stem Cells
Published on: February 22, 2017
12.8K
相关概念视频
02:59Animal Mitochondrial Genetics
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...